License Agreements - Additional Information (Details) - USD ($)		1 Months Ended						3 Months Ended		6 Months Ended
	Jul. 20, 2021	Aug. 31, 2021	May 31, 2021	Jan. 31, 2021	Apr. 30, 2020	Mar. 31, 2020	Feb. 29, 2020	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
License Agreements [Line Items]
In-process research and development									$ 5,488,000	$ 2,000,000	$ 9,168,000
Common Stock | IPO
License Agreements [Line Items]
Stock issued and sold	21,562,500
License Agreement | NiKang Therapeutics, Inc.
License Agreements [Line Items]
Upfront payment							$ 5,000,000.0
Reimbursement of certain initial manufacturing costs							400,000
Payment for US patent application					$ 7,000,000.0
In-process research and development								$ 0	0	0	0
License Agreement | NiKang Therapeutics, Inc. | First Licensed Product
License Agreements [Line Items]
Payment of development and regulatory milestone obligation				$ 4,000,000.0
License Agreement | NiKang Therapeutics, Inc. | First Licensed Product | Maximum
License Agreements [Line Items]
Development and regulatory milestone payments obligation							16,000,000.0
Commercial milestone payments obligation							157,000,000.0
License Agreement | NiKang Therapeutics, Inc. | Second Licensed Product
License Agreements [Line Items]
Development and regulatory milestone payments obligation							12,000,000.0
Commercial milestone payments obligation							$ 151,000,000.0
License Agreement | Katmai Pharmaceuticals, Inc.
License Agreements [Line Items]
Upfront payment						$ 5,700,000
In-process research and development								0	0	2,000,000.0	0
License Agreement | Katmai Pharmaceuticals, Inc. | Series B-1 Convertible Preferred Stock and Series B-2 Convertible Preferred Stock
License Agreements [Line Items]
Stock issued, value						$ 2,700,000
License Agreement | Katmai Pharmaceuticals, Inc. | Series B-1 Convertible Preferred Stock and Series B-2 Convertible Preferred Stock | IPO
License Agreements [Line Items]
Conversion of convertible preferred stock into common stock						395,555
License Agreement | Katmai Pharmaceuticals, Inc. | Series B-1 Convertible Preferred Stock
License Agreements [Line Items]
Stock issued, value					$ 1,800,000
Stock issued and sold					356,000
License Agreement | Katmai Pharmaceuticals, Inc. | Series B-2 Convertible Preferred Stock
License Agreements [Line Items]
Stock issued, value				$ 900,000
Stock issued and sold				118,666
License Agreement | Katmai Pharmaceuticals, Inc. | Maximum
License Agreements [Line Items]
Development and regulatory milestone payments obligation						$ 24,000,000.0
Commercial milestone payments obligation						$ 101,000,000.0
License Agreement | LifeArc
License Agreements [Line Items]
Upfront payment					$ 0
In-process research and development								0	0	0	0
One-time license payment					75,000
License Agreement | LifeArc | Maximum
License Agreements [Line Items]
Development and regulatory milestone payments obligation					11,000,000.0
Sales milestone payments obligation					$ 50,000,000.0
License Agreement | The Regents
License Agreements [Line Items]
Upfront payment			$ 50,000
In-process research and development								$ 0	$ 5,500,000	$ 0	$ 5,500,000
Sales milestone payments obligation			$ 2,000,000.0
Percentage of third tier sublicensing fees			30.00%
Cash payments in license agreement upon achievement of corporate milestone		$ 1,700,000
License Agreement | The Regents | Common Stock
License Agreements [Line Items]
Stock issued and sold			944,945
License Agreement | The Regents | Maximum
License Agreements [Line Items]
Development and regulatory milestone payments obligation			$ 6,400,000